Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice from Type 1 Diabetes (T1D)
cyteir2018-03-07T22:46:39-05:00Cyteir Therapeutics Announces Study Showing RAD51 Modulators Protect Diabetic Mice from Type 1 Diabetes (T1D) --Data demonstrates that therapeutic targeting of the AID/RAD51 axis in B cells may block development of T1D by converting B cells to a suppressive population capable of inhibiting disease development -- --First demonstration of synthetic lethal pairs in a [...]